What is Cabtreo (alendronate sodium and vitamin D3) and how should it be used for osteoporosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

CABTREO: Topical Acne Treatment (Not an Osteoporosis Medication)

CABTREO is a topical gel containing clindamycin phosphate 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1% used exclusively for treating acne vulgaris on the skin—it has no relationship to osteoporosis treatment or bone health. 1

What CABTREO Is

CABTREO is a prescription topical medication combining three active ingredients for acne treatment:

  • Clindamycin phosphate (antibiotic)
  • Adapalene (retinoid)
  • Benzoyl peroxide (antimicrobial/keratolytic)

This appears to be a case of confusion with similarly-named medications. You may be thinking of combination products containing alendronate (a bisphosphonate) with vitamin D3 for osteoporosis treatment, which have entirely different names and formulations.

How to Use CABTREO (For Acne Only)

Application Instructions:

  • Apply once daily to affected areas after cleansing and drying the skin 1
  • Dispense one pea-sized amount from the pump
  • Dot onto six areas of the face (chin, both cheeks, nose, both sides of forehead) 1
  • Spread gently over the entire face
  • Wash hands after application

Critical Warnings:

  • For topical use only—not for oral, ophthalmic, or intravaginal use 1
  • Avoid eyes, mouth, mucous membranes, and broken/eczematous/sunburned skin 1
  • Store at room temperature ≤77°F (25°C), keep upright, away from heat 1

If You're Looking for Osteoporosis Treatment

For postmenopausal osteoporosis, first-line treatment is oral bisphosphonates (alendronate or risedronate) combined with adequate calcium (1000-1200 mg daily) and vitamin D3 (800-1000 IU daily). 2

Combination products containing alendronate 70 mg with cholecalciferol (vitamin D3) 2800 IU are available as once-weekly tablets for osteoporosis treatment 3, 4. These provide proven fracture reduction at vertebral, non-vertebral, and hip sites 2.

Key osteoporosis treatment principles:

  • Alendronate, risedronate, zoledronic acid, or denosumab reduce hip and vertebral fractures in women with known osteoporosis 2
  • Treatment duration should be 5 years initially 2
  • Vitamin D supplementation (800-1000 IU daily) is essential for all patients on bone-protective therapy 5
  • Adequate calcium intake (1000-1200 mg daily through diet or supplements) is required 5

CABTREO has no role in bone health or osteoporosis management whatsoever.

Related Questions

How should I manage mild hypercalcemia in a woman with osteoporosis taking alendronate (Fosamax), calcium and vitamin D supplements?
What is the recommended management for a patient with osteoporosis who has been treated with alendronate (Fosamax)?
What is the best course of action for managing osteoporosis in an 88-year-old female with decreased bone density on Alendronate (alendronic acid)?
In a patient with osteoporosis taking alendronate 70 mg weekly who has an intact parathyroid hormone level of 84 pg/mL, how should this be managed?
Should calcium and vitamin D (cholecalciferol) be co‑administered with alendronate in an elderly female patient with a history of fracture?
Can dexmedetomidine be administered to a patient with meningitis?
What antihypertensive therapy is recommended for patients with autosomal dominant polycystic kidney disease?
Should imatinib be continued in a chronic myeloid leukemia patient who presents with diarrhea, abdominal pain, marked leukocytosis, normal lactate, stable vital signs, negative Clostridioides difficile PCR, and is receiving empiric piperacillin‑tazobactam?
How should I approach a transgender adolescent with body dysmorphic disorder whose parents do not acknowledge the teen’s preferred pronouns?
Why would azithromycin be effective in viral infections?
What are the nurse practitioner‑specific recommendations for evaluating and managing chronic stress‑induced hypothalamic‑pituitary‑adrenal (HPA) axis dysregulation in patients with major depressive disorder (MDD)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.